Smoking Cessation of Young Adults

Smoking Cessation of Young Adults in Northern Finland

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-000596-16-FI

Enrollment

Unknown

Registered

2012-02-08

Start date

2012-03-19

Completion date

Unknown

Last updated

2016-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy daily smoking young adults aged 18-26 years MedDRA version: 14.1 Level: PT Classification code 10053325 Term: Smoking cessation therapy System Organ Class: 10042613 - Surgical and medical procedures

Interventions

Trade Name: Champix Product Name: Champix Pharmaceutical Form: Tablet CAS Number: 375815-87-5 Other descriptive name: VARENICLINE TARTRATE Concentration unit: mg milligram(s) Concentration type: range

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -healthy daily smokers aged 18-26 years -motivation to quit smoking and to attend the 12 months follow-up -dailys smoker has smoked at least 1cig/day daily during the last month and has smoked at least 100 cig ever -a non-smoker has not smoked during the last month and has smoked ever less than 50cig -minor allergies or mild asthma without daily medication is acceptable -healthy non-smokers Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 300 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - any chronic disease with daily medication -known allergy to study medications(varenicline,nicotine patch,nicotine gum) -any substance and /or alcohol abuse -gravidity or plan to become pregnant during the study period -lactation period of women -drop-outs are counted as current smokers

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate smoking habits, prevalence of smoking and smoking cessation in young daily smokers. ;Secondary Objective: To assess the effectiveness of different aids used in smoking cessation of the study objectives;Primary end point(s): To measure the continuous abstinence rate	—

Secondary

Measure	Time frame
Secondary end point(s): To assess the abstinence by urine cotinine testing	—

Countries

Finland

Contacts

Public ContactTuula Toljamo

Lapland Hospital District/ Lapland Central Hospital

tuula.toljamo@lshp.fi+358163283201

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026